- Zacks Small Cap Research via Yahoo FinanceAug 29 17:20 PM
V) announced that the Phase 2b dose-ranging, efficacy study of ATB-346 had commenced. Study subjects will receive once daily doses of placebo or ATB-346 (150 mg, 200 mg, or 250 mg) over ...
- KOLR - KSFX Ozarks48 minutes ago
- Law.com2 days ago
- SCOTUSblog6 days ago